Cutaneous CCL13 mRNA and protein expression in vitiligo; a new insight to its immunopathogenesis

Document Type : Original Article

Authors

1 Department of Dermatology, Venereology and Andrology, Faculty of Medicine, Suez Canal University, Ismailia, Egypt

2 Department of Medical Biochemistry and Molecular Biology, Faculty of Medicine, Suez Canal University, Ismailia, Egypt

3 Clinical Sciences Department, College of Medicine, University of Sharjah, United Arab Emirates Department of Pathology, Faculty of Medicine, Suez Canal University, Ismailia, Egypt

Abstract

Background: Vitiligo is an acquired emotionally distressing skin depigmenting immune related disorder yielded by selective melanocyte death through type 1 immune response and an emerging participation of type 2 immune response. CCL13 is a hallmark in type 2 helper T cells immune-related skin diseases. Our previous study showed that CCL13 expression, a type 2 immune response marker, was higher in vitiligo patients than controls. Aim: To investigate the relationship between mRNA and protein expressions of CCL13 in vitiligo lesions.  Subjects and methods: This cross-sectional study comprised 30 non-segmental marginal recent vitiligo lesions. Immunohistochemistry, and real-time polymerase chain reaction were used to assess CCL13 protein expression, and relative CCL13 mRNA gene expression, respectively. Results: CCL13 is expressed at both genetic and tissue levels as there is relation between mRNA and protein expressions of CCL13 in vitiligo lesions. Conclusion: Relation between mRNA and protein expressions of CCL13 in vitiligo lesions may suggest its positive participation in vitiligo immune pathogenesis

Keywords

Main Subjects

Files

Share

How to cite

Statistics